Report Overview

Global Drugs for Vulvovaginal Candidiasis (VVC) Market Forecast and Trends

The global Drugs for Vulvovaginal Candidiasis (VVC) market is anticipated to grow nearly at a CAGR of 3.76% to reach US$ 1,006 million by 2026. The key drivers of growth are projected to be the increase in the number of patients affected by candidiasis infection, and high acceptance due to innovative vulvovaginal candidiasis drugs are predicted to be major drivers of market growth over the forecast period. Increasing consumer awareness of candidiasis and increasing number of treatment options are major drivers of candidiasis market growth.

Moreover, factor driving the market growth is expected to be the increasing awareness of hygiene among people in developing countries. The drug is formulated in various forms, including pessary, cream, and others. The increasing number of patients affected by candidiasis infection, combined with the growing acceptance of innovative drugs, are some of the key factors expected to stimulate demand from the vulvovaginal candidiasis market. Globally, market players are involved in innovating new product development, which is likely to support market growth over the forecast period. In addition, approaches such as mergers and business behemoths acquisitions and partnerships are possible to provide a tailwind to the worldwide market for vulvovaginal candidiasis (VVC) drugs.

Global Drugs for Vulvovaginal Candidiasis (VVC) Market Overview:

Candidiasis is a form of infection caused by yeast–candida, often known as a fungus that is found in the human body. It is usually present in areas like the mouth, the abdomen, and the skin. This dormant yeast can contribute to candida infection at any point in a person's life and is closely linked to the person's level of immunity. There are various types of infections caused by candidiasis, such as thrush / oropharyngeal candidiasis, genital yeast infection / invasive infection, and cutaneous candidiasis Medications for Vulvovaginal Candidiasis is a drug used to treat vulvovaginal candidiasis. Vulvovaginal Candidiasis is also referred to as vaginal thrush. Numerous types of drugs are available for Vulvovaginal Candidiasis, including miconazole, clotrimazole, fluconazole, econazole, and others. The drug is formulated in different types, including cream, pessary, and others. An increase in the number of patients affected by candidiasis infection and high uptake due to innovative medicines would help boost the global market for vulvovaginal candidiasis drugs.

Growth drivers

Rising Incidences of Candidiasis Driving Adoption of VVC Drugs Market

The increased incidence of VVC infections is the main contributing factor projected to fuel the growth of the demand for VVC drugs over the forecast period. Increasing rising R&D investment deployed by pharmaceutical manufacturers for the production of novel antifungals, market expansion is strongly supported. Azoles are the class of drugs most widely used to treat systemic fungal infection. These are known as triazoles and imidazoles. Triazoles such as fluconazole, voriconazole and itraconazole have a strong wide-spectrum action and offer higher levels of safety compared to other therapeutic agents. The triazoles have less adverse effects and extreme reactions between products and medicines and have enhanced pharmocinetic properties. Completely these advantages lead to the current azoles supremacy among other drug classes.

Increasing R&D expenditure and the expansion of the product pipeline by pharmaceutical manufacturers In recent years, the market for the treatment of fungal diseases has sprouted a number of highly effective and safe antifungal agents. Some of the most effective therapies on the market are terbinafine, itraconazole, fluconazole. Increasing R&D expenditure and expanding the pharmaceutical manufacturers ' advanced product pipeline for anti-infective development is one of the key factors contributing to the growth of the antifungal drug sector. Players focus on developing effective therapeutic agents in immunocompromised patients to treat systemic fungal infections. Different public-private collaboration arrangements to develop new technologies are expected to provide tremendous growth opportunities for the sector.

Restraints

Narrow Pipeline Molecules

High rates of morbidity and mortality associated with candidiasis clearly indicate the ineffectiveness of conventional antifungal treatment to treat candidiasis. Fungal cells are eukaryotic, making it even more difficult to produce antifungal drugs. Therefore, selective pathogen-specific targets for drug discovery and development are much more difficult to identify. Clinically, the current options available for combat candidiasis are limited to three types of antifungal agents-polyene, azoles, and echinocandins. The availability of herbal alternative to fungal infection can hinder market growth.

Global Drugs for Vulvovaginal Candidiasis (VVC) Market: Formulation Type

The Vulvovaginal Candidiasis (VVC) Drug market, based on formulation type, segmented into Topical (Cream, Lotion, Gel, Ointment, Aerosol, Foam, Powder, Solution etc.), Pessary (Suppositories, Kit) and Oral (Tablet, Capsule, Powder for Suspension etc.). Amidst the formulation type, the Topical segment will fuel the market for Vulvovaginal Candidiasis Drugs due to rising demand from small and medium-sized enterprises, and various industry verticals would provide enough room for market growth over the forecast period. Topical is used to treat diseases of vaginal yeast. This decreases vaginal pain, itching, and discharge with this condition. This drug is an antifungal azole. It works by preventing the growth of the infection-causing yeast (Fungus).

Global Drugs for Vulvovaginal Candidiasis (VVC) Market: Drug Type

The Vulvovaginal Candidiasis (VVC) Drug market, based on Drug Type, segmented into Miconazole, Clotrimazole, Fluconazole, Econazole, and Other (Itraconazole, Nystatin, Tioconazole, amphotericin B Etc.). The Fluconazole drug in the Drug Type segment is widely used for the treatment of the Vulvovaginal Candidiasis (VVC). Other treatments may be required for infections that are more severe, that don't get better, or that keep coming back after they get better. These include multiple doses of fluconazole obtained by mouth or other medicines used inside the vagina, such as boric acid, nystatin, or flucytosine. Fluconazole is a drug that is most effective and safe. Fluconazole is also available as a generic medication. A number of fungal and yeast infections are prevented and treated with fluconazole.

Global Drugs for Vulvovaginal Candidiasis (VVC) Market: End User

Based on End user, the Vulvovaginal Candidiasis (VVC) Drug market segmented into the hospitals, clinics, and Pharmacy. The hospital in the End user segment is widely used for the treatment of the Vulvovaginal Candidiasis (VVC). Hospital is predicted to be the fastest growing application segment on the global Vulvovaginal Candidiasis (VVC) Drug market and its dominance over the forecast period is expected to be maintained. Vulvovaginal Candidiasis (VVC) Drug is augmenting due to increasing consumer inclination towards maintaining aesthetic appearance. Increase in Number of Patients Affected by Candidiasis Infection and Increasing consumer awareness about candidiasis and growing number of treatments driving the hospital market.

Global Drugs for Vulvovaginal Candidiasis (VVC) Market: Regional insights

By geography, the global Drugs for Vulvovaginal Candidiasis (VVC) Market segregated into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. North America is expected to dominate the market, due to the growing incidence of vulvovaginal candidiasis (VVC) among the population in the region would drive the growth of the sector. The prevalence of sedentary lifestyles has a major impact on women's health. Changing lifestyles, particularly among the working population, had an impact on women's health, which has contributed to these illnesses. In addition, changes in eating habits have influenced health, especially among the working women population.

Drugs for Vulvovaginal Candidiasis (VVC) Market: Competitive Landscape

The major market players in the Global Drugs for Vulvovaginal Candidiasis (VVC) are Bayer, Perrigo, J & J, Pfizer, Bristol-Myers Squibb, Effik, Teva, Sanofi, Cisen Pharmaceutical, Kingyork Group, Janssen, Actavis, Tianjin Kingyork Group, Tianjin Pacific Pharmaceutical, Lunan Pharmaceutical, Viamet Pharmaceuticals, and other Prominent Players are expanding their presence in the market by implementing various innovations and technologies.

The objective of the Study:

To analyze and forecast the global Drugs for Vulvovaginal Candidiasis (VVC) market size of the market, in terms of value.

To examine the careful market segmentation and forecast the market size, in terms value, based on the region by segmenting the Global Drugs for Vulvovaginal Candidiasis (VVC) market into five regions, namely, North America, Europe, Asia Pacific, Middle East, South America and their leading countries.

To outline, categorized and forecast the global Drugs for Vulvovaginal Candidiasis (VVC) market based on the Formulation Type, Drug type, and End user.

To examine competitive developments like technological advancement, services, and regulative framework within the global Drugs for Vulvovaginal Candidiasis (VVC) Market.

To highlight the impact analysis of the factors, affecting the market dynamics such as drivers, restraints, opportunities, and challenges.

To strategically profile the key players and comprehensively analyze their market shares along with detailing the competitive landscape for market leaders.

Scope of the Report

By Formulation Type

·         Topical (Cream, Lotion, Gel, Ointment, Aerosol, Foam, Powder, Solution etc.)

·         Pessary (Suppositories, Kit)

·         Oral (Tablet, Capsule, Powder for Suspension etc.)

By Drug Type

·         Miconazole

·         Clotrimazole

·         Fluconazole

·         Econazole

·         Others (Itraconazole, Nystatin, Tioconazole, amphotericin B Etc.)

By End User

·         Hospital

·         Clinic

·         Pharmacy

By Region:

·         Asia Pacific

·         North America

·         Europe

·         Middle East & Africa

·         Latin America

Business Questions answer by the report

·         How will the market drivers, restraints and opportunities affect the market dynamics?

·         What will be the market size in terms of value and volume and market statistics with a detailed classification?

·         Which segment dominates the market or region and one will be the fastest growing and why?

·         A comprehensive survey of the competitive landscape and the market participant players

·         Analysis of strategy adopted by the key player and their impact on other players.

Customization Scope for the Client

Client satisfaction is our first and last priority and that is why BlueWeave Consulting offers customization according to Company’s specific needs. The following customization options are available for the report:

Additional Company Information

·         With five additional company detail analysis

·         Additional country analysis

·         Detailed segment analysis

1.    Research Framework

1.1. Research Objective

1.2. Product Overview

1.3. Market Segmentation

2.    Research Methodology

2.1. Qualitative Research

2.1.1.   Primary & Secondary Sources

2.2. Quantitative Research

2.2.1.   Primary & Secondary Sources

2.3. Breakdown of Primary Research Respondents, By Region

2.3.1.   Secondary Research

2.3.2.   Primary Research

2.4. Breakdown of Primary Research Respondents

2.5. Market Size Estimation

2.6. Assumption for the Study

2.7. Market Breakdown & Data Triangulation

3.    Global Drugs for Vulvovaginal Candidiasis (VVC) Market Industry Insights

3.1. DROC Analysis

3.1.1.   Growth Drivers

3.1.2.   Restraints

3.1.3.   Opportunities

3.1.4.   Challenges

3.2. Technological Landscape

3.3. Regulatory Framework

3.4. Company market share analysis, 2019

3.5. Porter’s Five forces analysis

3.5.1.   Bargaining Power of Suppliers

3.5.2.   Bargaining Power of Buyers

3.5.3.   Threat of New Entrants

3.5.4.   Threat of Substitutes

3.5.5.   Intensity of Rivalry

4.    Global Drugs for Vulvovaginal Candidiasis (VVC) Market Overview

4.1. Market Size & Forecast 2016-2026

4.1.1.   By Value (USD) 

4.2. Market Share & Forecast

4.2.1.   By Formulation Type

4.2.1.1.       Topical (Cream, Lotion, Gel, Ointment, Aerosol, Foam, Powder, Solution etc.)

4.2.1.2.       Pessary (Suppositories, Kit)

4.2.1.3.       Oral (Tablet, Capsule, Powder for Suspension etc.)

4.2.2.   By Drug Type

4.2.2.1.       Miconazole

4.2.2.2.       Clotrimazole

4.2.2.3.       Fluconazole

4.2.2.4.       Econazole

4.2.2.5.       Others (Itraconazole, Nystatin, Tioconazole, amphotericin B Etc.)

4.2.3.   By End User

4.2.3.1.       Hospital

4.2.3.2.       Clinic

4.2.3.3.       Pharmacy

4.2.4.   By Region

4.2.4.1.       North America

4.2.4.2.       Europe

4.2.4.3.       Asia Pacific

4.2.4.4.       Latin America

4.2.4.5.       Middle East & Africa

5.    North America Drugs for Vulvovaginal Candidiasis (VVC) Market

5.1. Market estimates & forecast

5.1.1.   By Formulation Type

5.1.2.   By Drug Type

5.1.3.   By End user

5.1.4.   By Country

5.1.4.1.       U.S

5.1.4.2.       Canada

6.    Europe Drugs for Vulvovaginal Candidiasis (VVC) Market

6.1. Market estimates & forecast

6.1.1.   By Formulation Type

6.1.2.   By Drug Type

6.1.3.   By End user

6.1.4.   By Country

6.1.4.1.       Germany

6.1.4.2.       U.K

6.1.4.3.       France

6.1.4.4.       Italy

6.1.4.5.       Rest of Europe

7.    Asia Pacific Drugs for Vulvovaginal Candidiasis (VVC) Market

7.1. Market estimates & forecast

7.1.1.   By Formulation Type

7.1.2.   By Drug Type

7.1.3.   By End user

7.1.4.   By Country

7.1.4.1.       China

7.1.4.2.       India

7.1.4.3.       Japan

7.1.4.4.       Rest of APAC

8.    Latin America Drugs for Vulvovaginal Candidiasis (VVC) Market

8.1. Market estimates & forecast

8.1.1.   By Formulation Type

8.1.2.   By Drug Type

8.1.3.   By End user

8.1.4.   By Country

8.1.4.1.       Brazil

8.1.4.2.       Argentina

8.1.4.3.       Rest of Latin America

9.    Middle East & Africa Drugs for Vulvovaginal Candidiasis (VVC) Market

9.1. Market estimates & forecast

9.1.1.   By Formulation Type

9.1.2.   By Drug Type

9.1.3.   By End user

9.1.4.   By Country

9.1.4.1.       Saudi Arabia

9.1.4.2.       UAE

9.1.4.3.       South Africa

9.1.4.4.       Rest of MEA

10.Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *

10.1.             Bayer

10.2.             Perrigo

10.3.             J & J

10.4.             Pfizer

10.5.             Bristol-Myers Squibb

10.6.             Effik

10.7.             Teva

10.8.             Sanofi

10.9.             Cisen Pharmaceutical

10.10.          Kingyork Group

10.11.          Janssen

10.12.          Actavis

10.13.          Tianjin Kingyork Group

10.14.          Tianjin Pacific Pharmaceutical

10.15.          Lunan Pharmaceutical

10.16.          Viamet Pharmaceuticals

10.17.          Other Prominent Players

* Financial information of non-listed Companies will be provided as per availability

**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable